Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.32 |
| ▸ | MTOR | P42345 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202424 | 0.81 | KDM4E (0.38) | KDM4E | |
| SCHEMBL202096 | 0.80 | PRMT5 (0.37) | PIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL202998 | 0.77 | MEN1 (0.38) | KDM4E | |
| SCHEMBL204000 | 0.72 | KDM4E (0.39) | KDM4E | |
| SCHEMBL202430 | 0.65 | NOS2 (0.44) | KDM4EPIK3CAPIK3CDPIK3CGMTOR | |
| SCHEMBL205143 | 0.63 | KDM4E (0.40) | KDM4EMTOR | |
| SCHEMBL204292 | 0.63 | KDM4E (0.47) | KDM4E | |
| SCHEMBL202353 | 0.62 | TLR7 (0.41) | — | |
| SCHEMBL203571 | 0.61 | KDM5B (0.39) | KDM4EMTOR | |
| SCHEMBL4302608 | 0.60 | KDM4E (0.40) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2007106852-A2 | SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | KDM4E 2419/4885PIK3CA 1007/4885PIK3CD 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.